Home›Clinical trials›Role of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Treatment

A study testing whether a GLP-1 medicine, semaglutide, can help people lose weight.

Recruiting now. Registry record last updated December 10, 2025.

Who can join
Adults 18+, have obesity or are overweight, BMI 27+.
What you take
Semaglutide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts
The full study runs about 3 years.
What you get
Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.
This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.
Check my fit →
Phase Not ApplicableSponsor Brigham and Women's HospitalDrug semaglutideClass GLP-1 RASites 1 USEnrollment target 30

What this study is for

Primary condition: Overweight and Obesity.

Full scientific study title: Role of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Treatment.

Who can join

Age18 and upSexAnyBMI27 or higher

Adults 18+, have obesity or are overweight, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

  • Age ≥18 years, body mass index (BMI) ≥30.0 kg/m2 or ≥27.0 kg/m2 with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension, prediabetes, dyslipidemia, obstructive sleep apnea,
  • Normal screening laboratory values,
  • Systolic BP \< 160 mmHg and diastolic BP \< 95 mmHg as determined from measurement during screening, using a random-zero device in the clinic and normal electrocardiogram, use of anti-hypertensive medications will be allowed except for mineralocorticoid receptor antagonists.

Key exclusion criteria

  • Diabetes mellitus,
  • Treatment with a glucose-lowering agent(s) or anti-obesity medication within 90 days of screening,
  • Treatment with a GLP-1 receptor agonist within 180 days,
  • Current treatment with beta-blocker, or steroids,
  • Pregnancy,

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Massachusetts1 site
  • Brigham and Women's Hospital
    Boston, Massachusetts
    Ezgi Caliskan Guzelce, MD

Timeline

Started enrolling: November 1, 2023. Expected completion: November 30, 2026. Last updated on ClinicalTrials.gov: December 10, 2025.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, editor of GLP Chart
John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact
Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.